- Home
- AVXL
as 07-26-2024 4:00pm EST
Anavex Life Sciences Corp is a clinical-stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system diseases with high unmet need. It analyzes genomic data from clinical studies to identify biomarkers, which are used to select patients that will receive the therapeutic benefit for the treatment of neurodegenerative and neurodevelopmental diseases. Its necessary compound ANAVEX 2-73 is being developed to treat Alzheimer's disease, Parkinson's disease, and potentially other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder. The company's operating segment is into developing novel therapies for the management of CNS diseases.
| Founded: | N/A | Country: | United States |
| Employees: | N/A | City: | NEW YORK |
| Market Cap: | 357.2M | IPO Year: | N/A |
| Target Price: | $40.00 | AVG Volume (30 days): | 1.1M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.51 | EPS Growth: | N/A |
| 52 Week Low/High: | $3.25 - $10.45 | Next Earning Date: | 08-06-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Anavex Life Sciences Corp. (AVXL)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Donhauser Peter D.O. | AVXL | Director | Jun 14 '24 | Buy | $3.64 | 2,835 | $10,319.40 | 5,000 | SEC Form 4 |
| Thomas Steffen | AVXL | Director | May 15 '24 | Buy | $4.52 | 5,000 | $22,600.00 | 5,000 | SEC Form 4 |
| MISSLING CHRISTOPHER U | AVXL | President and CEO | Mar 28 '24 | Sell | $5.11 | 73,380 | $374,971.80 | 1,250,210 | SEC Form 4 |
Latest Anavex Life Sciences Corp. News
AVXL Breaking Stock News: Dive into AVXL Ticker-Specific Updates for Smart Investing
Zacks
17 days ago
Mirum (MIRM) Gets EC Approval for Livmarli Label Expansion
Zacks
17 days ago
HilleVax (HLVX) Tanks as Norovirus Vaccine Study in Infants Fails
Simply Wall St.
a month ago
Institutions own 38% of Anavex Life Sciences Corp. (NASDAQ:AVXL) shares but individual investors control 59% of the company
GlobeNewswire
a month ago
Anavex Life Sciences to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference
GOBankingRates
2 months ago
5 Reasons a Biden Second Term Could Be a Financial Disaster for Boomers
AFP
2 months ago
Bumrah delivers as India beat Pakistan in low-scoring thriller
AFP
2 months ago
Italy beat Bosnia in final Euros warm-up
AFP
2 months ago
Trump loyalists proud to support 'felon' at Las Vegas rally
Compare AVXL vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "AVXL Anavex Life Sciences Corp. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.